entertainment -WSS

entertainment

author：leisure time 2025-10-01 05:45:03 Page View：224

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What to expect as Trump is arraigned on his Jan 6. indictment
Next article： At least 13 dead in Texas as scorching temps continue

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Physician groups backed by private equity giant lobby on mergers

PhysiciangroupsbackedbyWelsh,Carson,Anderson&Stowearelookingtoinfluencefederalmergerpolicy.Adobe

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

MollyFerguson/STATThisweek,anencouragingturnaroundforOcularTherapeutix,achatwithAlnylam’sCEOdefendin

entertainment

Wikipedia

explore

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves